364385-64-8

Basic information

• Product Name: Methyl cis-4-(Boc-aMino)cyclohexanecarboxylate
• Synonyms: Methyl cis-4-(Boc-aMino)cyclohexanecarboxylate;cis-Methyl 4-((tert-butoxycarbonyl)amino)cyclohexanecarboxylate
• CAS NO: 364385-64-8
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 257.32602
• Mol File: 364385-64-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl cis-4-(Boc-aMino)cyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl cis-4-(Boc-aMino)cyclohexanecarboxylate(364385-64-8)
• EPA Substance Registry System: Methyl cis-4-(Boc-aMino)cyclohexanecarboxylate(364385-64-8)

Safety Data

• Hazardous Substances Data: 364385-64-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl cis-4-(Boc-aMino)cyclohexanecarboxylate is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its Boc-protected amino group allows for the controlled formation of peptide bonds, facilitating the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl cis-4-(Boc-aMino)cyclohexanecarboxylate serves as a building block for the creation of agrochemicals with targeted pest control capabilities. Its unique structure contributes to the design of novel compounds that can effectively address agricultural challenges.
Used as a Reagent in Chemical Reactions:
Methyl cis-4-(Boc-aMino)cyclohexanecarboxylate is utilized as a reagent in various chemical reactions, enabling the synthesis of a wide range of organic compounds. Its presence can influence reaction pathways and outcomes, contributing to the discovery of new chemical entities.
Used as a Starting Material for Organic Synthesis:
Methyl cis-4-(Boc-aMino)cyclohexanecarboxylate is employed as a starting material for the preparation of various organic molecules with potential applications in medicine and agriculture. Its cyclohexane core and Boc-protected amino functionality provide a solid foundation for the construction of complex molecular architectures.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 61367-16-6 cis-4-aminocyclohexanecarboxylic acid methyl ester hydrochloride 
• 62456-15-9 methyl (1s,4s)-4-aminocyclohexane-1-carboxylate 
• 3685-23-2 cis-4-aminocyclohexane-1-carboxylic acid 
• 53292-90-3 cis-4-tert-butoxycarbonylaminocyclohexane-1-ylcarboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 118785-97-0 cis-4-amino-cyclohexanecarboxylic acid hydrochloride 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 

Downstream Products

• 791778-53-5 cis-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexanamine 
• 506427-91-4 tert-butyl (cis-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)carbamate 
• 847417-37-2 tert-butyl ((1s,4s)-4-(2-oxoethyl)cyclohexyl)carbamate 
• 509143-10-6 N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-2-(2-trifluoromethoxy-phenyl)-acetamide 
• 509142-66-9 benzyl [(cis-4-{[4-(methylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]carbamate 
• 509142-56-7 benzyl [(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]carbamate 
• 364385-65-9 [4-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 509142-53-4 tert-butyl ((cis)-4-((((benzyloxy)carbonyl)amino)methyl)cyclohexyl)carbamate 
• 509142-67-0 N²-(4-aminomethyl-cyclohexyl)-N⁴-methyl-quinazoline-2,4-diamine 
• 509142-63-6 N²-[cis-4-(aminomethyl)cyclohexyl]-N⁴,N⁴-dimethylquinazoline-2,4-diamine 

Relevant articles and documents

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

Copper-Catalyzed and Indium-Mediated Methoxycarbonylation of Unactivated Alkyl Iodides with Balloon CO

This work emphasizes the synthesis of alkyl esters via Cu-catalyzed and In-mediated alkoxycarbonylation of unactivated alkyl iodides in the presence of In or InI. The reactions were suitable for the preparation of primary, secondary, and even tertiary alkyl esters, representing an exceptionally rare example for the creation of quaternary carbon centers upon formation of esters. The preliminary mechanistic studies indicated that alkyl radicals were involved, and Cu/In/CO played a cooperative role in the carbonylation event.

D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine

Functionally selective G protein-coupled receptor ligands are valuable tools for deciphering the roles of downstream signaling pathways that potentially contribute to therapeutic effects versus side effects. Recently, we discovered both Gi/o-bi

Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists

The optimization of the distance between two key pharmacophore features within our first hit compounds 1a and 2a led to the identification of a new class of potent non-peptidic antagonists for the MCH-R1, based around 4-amino-2-cyclohexylaminoquinazolines. In particular, ATC0065 (2c), N2-[cis-4-({2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl}amino)cyclohexyl]-N4,N4-dimethylquinazoline-2,4-diamine dihydrochloride, bound with high affinity to the MCH-R1 (IC50 value of 16 nM) and showed good metabolic stability in liver microsomes from human and rat.

Heterocycle derivatives and drugs

There is provided an excellent novel analgesic having an analgesic effect which is effective widely against a pain including a chronic pain or an allodynia accompanied with herpes zoster by acting on a nociceptin receptor. The present invention relates to a compound represented by the following formula: or a salt thereof. In the formula, X and Y are same or different and each represents a nitrogen atom or CH; R1 represents a hydrogen atom or alkyl and the like; A1 and A2 are same or different and each represents a single bond or a divalent aliphatic hydrocarbon group; Q represents a single bond, cycloalkylene group, phenylene group or divalent heterocyclic group; R2A, R2B, R2C and R2D are same or different and each represents a hydrogen atom, alkyl or phenyl; E represents a ethenylene group or —NRCO— (in which R is hydrogen or alkyl) and the like; R3 represents a phenyl group or a heterocyclic group; R4 and R5 are same or different and each represents a hydrogen atom, alkyl, alkoxy, aralkyloxy, halogen, nitro, hydroxy, alkoxycarbonyl, —NR6R7 (in which R6 and R7 are same or different and each represents a hydrogen atom or alkyl) and the like.

VLA-4 INHIBITORS

The present invention relates to a compound represented by the following formula (I): (wherein, W represents WA-A1 -WB - (in which, WA is substituted or unsubstituted aryl, etc., A1 is -NR1-, single bond, -C(O)-, etc., and WB is substituted or unsubstituted arylene, etc.), R is single bond, -NH-, -OCH2-, alkenylene, etc., X is -C(O) -CH2-, etc., and M is, for example, the following formula: (in which, R11, R12 and R13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14 is hydrogen or lower alkyl, Y represents -CH2-O-, etc., Z is substituted or unsubstituted arylene, etc., A2 is single bond, etc, and R10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.